FTC opened comments on a Caremark settlement over insulin and pharmacy-benefit practices
The FTC accepted a proposed order requiring CVS Caremark and Zinc to change rebate, formulary, insulin-cost and pharmacy-access practices. The public has 30 days from the July 14 announcement to comment before the order can become final. (sources: www.ftc.gov, www.statnews.com)
The FTC has settled a lawsuit with CVS Caremark concerning claims of manipulated insulin prices and restricted access. The settlement includes provisions for out-of-pocket savings for consumers.
- The FTC settled a lawsuit with CVS Caremark over allegations of insulin price manipulation.
- The settlement aims to improve access to insulin and provide savings for consumers.
- The FTC is currently accepting public comments on the settlement.
Why it matters
This settlement could impact insulin pricing and access for consumers, influencing pharmacy-benefit practices.
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on Prescription drug prices
See the current decision, choose your position, and send a message through the issue page.
Take action on Prescription drug pricesSources used · 5 sources